Last reviewed · How we verify
PGE1 tablet
At a glance
| Generic name | PGE1 tablet |
|---|---|
| Also known as | Prostaglandin E1 |
| Sponsor | Hillel Yaffe Medical Center |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Laminaria Japonicum Followed by Misoprostol Versus Misoprostol Alone for Mid-Trimester Abortion Induction in Scarred Uterus (PHASE4)
- A Study of MUSE Device for Midlife Women (NA)
- The Effect of a Music Intervention on Postictal Agitation in Electroconvulsive Therapy Patients (NA)
- Cervical Ripening With Misoprostol vs Isosorbide Mononitrate ; A Parallel -Arm Randomized Controlled Trial (NA)
- Mindfulness Intervention for Post-Covid Symptoms (NA)
- Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation
- Pain and Stress Detection and Relief in People With Dementia (NA)
- Letrozole in Induction of Abortion of Anembryonic Pregnancy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PGE1 tablet CI brief — competitive landscape report
- PGE1 tablet updates RSS · CI watch RSS
- Hillel Yaffe Medical Center portfolio CI